A randomized, prospective, open-label, controlled trial comparing the efficacy of omitting H2 antagonists versus famotidine in premedication protocol for prophylaxis of taxane hypersensitivity reactions
Phase 3
- Conditions
- A randomized, prospective, open-label, controlled trial comparing the efficacy of omitting H2 antagonists versus famotidine in premedication protocol for prophylaxis of taxane hypersensitivity reactions
- Registration Number
- TCTR20220913005
- Lead Sponsor
- /A
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 140
Inclusion Criteria
Cancer patients who received taxane chemotherapy regimen
Exclusion Criteria
1.History of severe Hypersensitivity reactions from taxane regimen
2.Severe hepatic impairment (bilirubin >5xULN or AST/ALT >10xULN)
3. Patients with a history of severe hypersensitivity reactions to taxanes such as bronchospasm, hypotension.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hypersensitivity reactions every 3 week of six-cycle course of chemotherapy grading of Hypersensitivity reactions
- Secondary Outcome Measures
Name Time Method /A N/A N/A